Epitalon Peptide: Dosage, Reconstitution, and Longevity Protocol
Epitalon Peptide
Epitalon (also called Epithalon or AEDG) is a synthetic tetrapeptide studied primarily in aging, telomere, pineal, and circadian research. Laboratory studies have investigated effects on telomerase activity and telomere biology, while additional research has explored melatonin-related and age-associated cellular pathways. Human clinical evidence remains limited and should not be interpreted as proof that Epitalon extends lifespan or reverses aging.
How Epitalon Works
Telomerase + Telomere Research → Cellular Aging Pathways → Pineal + Circadian Research
Epitalon has been investigated for effects on telomerase activity, telomere biology, gene expression, and pineal-related signaling. Telomerase activation has been demonstrated in cellular models, but these mechanistic findings should not be interpreted as established human lifespan extension.
Activates telomerase enzyme activity
Supports maintenance of telomere length
Influences pineal gland signaling
May support melatonin production and circadian rhythm balance
Typical Research Protocol
Short Research Cycle → Telomerase + Telomere Research → Cellular Aging Pathways
Days 1–10
Starting Phase
Dose
5 mg daily
Units
30 units
Volume
0.30 mL
Frequency
Once daily
Days 11–20
Optional Extension
Dose
5–10 mg daily
Units
30–60 units
Volume
0.30–0.60 mL
Frequency
Once daily
Higher Research-Use Range
Higher Range
Dose
10–20 mg daily
Units
60–120 units
Volume
0.60–1.20 mL
Frequency
Once daily
Volume Note:
At the 50 mg / 3.0 mL concentration, 20 mg equals approximately 120 units or 1.20 mL total. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
At the 50 mg / 3.0 mL concentration, 20 mg equals approximately 120 units or 1.20 mL total. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
Research Duration
Typical Cycle
10–20 days
Commonly Discussed Break
Several months
Clinical Standard
No universal required off-period established
Simple Approach:
Epitalon is commonly discussed in short research-use periods rather than continuous administration. The framework shown here begins with a fixed daily amount and allows an optional extension, but no standardized human dose-escalation schedule has been established.
Epitalon is commonly discussed in short research-use periods rather than continuous administration. The framework shown here begins with a fixed daily amount and allows an optional extension, but no standardized human dose-escalation schedule has been established.
Human Research Context
Human research exists, but the clinical evidence base is relatively limited and heterogeneous.
Some published work has evaluated pineal, melatonin, telomere, and age-related outcomes.
Many frequently cited longevity findings also involve Epithalamin, a bovine pineal peptide extract, which should not automatically be treated as equivalent to synthetic Epitalon.
Laboratory evidence for telomerase activity does not establish human lifespan extension.
How to Use (Cycle, Timing & Injection)
PrimarySubcutaneous injection
WhereSubcutaneous: abdomen, thigh, or upper arm
AlternativeIntramuscular injection
ExperimentalIntranasal or sublingual
OralLowest bioavailability
Research Duration & Reassessment
Research-Use Cycle
10–20 days
Commonly Discussed Break
Several months
Clinical Standard
No universal required off-period established
Research context:
Short treatment periods appear throughout the Epitalon literature, but there is no universally established human cycle length or required 6–12 month washout period. Longer breaks are best described as research-use practice rather than a clinical requirement.
Short treatment periods appear throughout the Epitalon literature, but there is no universally established human cycle length or required 6–12 month washout period. Longer breaks are best described as research-use practice rather than a clinical requirement.
Timing Guidance
Often taken in the evening to align with circadian rhythm signaling.
Some protocols use morning dosing depending on goals.
Consistency during the cycle is more important than exact time of day.
Avoid constantly changing timing during a cycle.
Use Notes
Subcutaneous injection is the most commonly discussed method.
Epitalon is typically used in short activation cycles rather than long-term dosing.
Effects are driven by pathway activation, not continuous exposure.
Long breaks between cycles allow biological signaling to stabilize.
Simple takeaway
Epitalon is not used like most peptides. It is run in short cycles (10–20 days), then stopped for months while the effects continue in the background.
Epitalon is not used like most peptides. It is run in short cycles (10–20 days), then stopped for months while the effects continue in the background.
Reconstitution & Dosing
Example Vial10 mg
Water Option 12 mL → 5 mg/mL
Water Option 25 mL → 2 mg/mL
Conversion1 unit = 0.01 mL
Example Dose Conversions
1 mg = 0.2 mL (20 units @ 5 mg/mL)
2.5 mg = 0.5 mL (50 units)
5 mg = 1.0 mL (100 units)
Reconstitution Steps
Draw bacteriostatic water
Inject slowly down vial wall
Gently swirl (do not shake)
Allow solution to fully dissolve
Refrigerate immediately after mixing
Storage & Shelf Life
Lyophilized (Unmixed)
Refrigerate at 2–8°C for short-term storage
Freeze at −20°C for long-term storage
Estimated shelf life: ~12–24 months refrigerated, longer if frozen
Protect from light, heat, and moisture
Reconstituted (Mixed)
Store at 2–8°C (36–46°F)
Best used within 30 days
Avoid repeated temperature changes
Discard if cloudy or discolored
Best Practice
Epitalon is often stored long-term before use due to infrequent cycling. Once mixed, use consistently within the cycle window.
Epitalon is often stored long-term before use due to infrequent cycling. Once mixed, use consistently within the cycle window.
Cycle Strategy & Time Between Cycles
10–20 Day Research Cycle → Reassess → Extended Break → Repeat if Appropriate
Cycle Structure
Research-Use Cycle
10–20 days
Use Style
Short, defined research periods
Continuous Use
Not the typical research framework
Time Between Cycles
Commonly Discussed Break
Several months
Clinical Standard
No universal required off-period established
Longer breaks allow time to reassess before considering another research-use cycle
Published research does not establish that a specific 6–12 month break is required
Repeated annual or semiannual cycling should be viewed as a research-use framework rather than a validated clinical schedule
Key idea:
Epitalon is generally discussed in short research-use periods rather than continuous administration. Short treatment periods appear in the research literature, but no universal human schedule has established exactly how long someone must wait before another cycle.
Epitalon is generally discussed in short research-use periods rather than continuous administration. Short treatment periods appear in the research literature, but no universal human schedule has established exactly how long someone must wait before another cycle.
Monitoring During Use
Sleep quality and circadian rhythm
Energy levels and recovery
Mood and cognitive clarity
Overall sense of rest and recovery
Benefits
Laboratory studies have investigated Epitalon for telomerase activity and telomere-related cellular effects
Research has explored pineal, melatonin, and circadian signaling
Preclinical studies have examined age-related cellular and oxidative-stress pathways
Some human research has evaluated age-associated and pineal-related outcomes
Human lifespan extension and broad anti-aging benefits have not been established in controlled clinical trials
Potential Side Effects
Injection-site irritation or discomfort may occur with subcutaneous administration
Sleep, circadian, or alertness response may vary between individuals
Human adverse-effect frequency has not been well established for modern injectable research-use protocols
Long-term safety of repeated high-dose or frequent cycles remains uncertain
Stacking Considerations
Epitalon is sometimes discussed alongside other longevity, mitochondrial, or neuroendocrine research compounds.
Controlled human research has not established specific Epitalon combination protocols.
Combining multiple research compounds can make individual effects and adverse responses harder to evaluate.
Evidence for an individual compound should not automatically be interpreted as evidence for a combined longevity stack.
Important Notes
Epitalon is a synthetic tetrapeptide also known as Epithalon or AEDG.
Laboratory research has demonstrated effects on telomerase and telomere-related biology, but this does not establish human lifespan extension.
Human research exists but remains limited compared with established clinical therapies.
Epitalon should not be treated as interchangeable with Epithalamin, the bovine pineal peptide extract used in some older research.
No standardized human dose, required cycle length, maintenance regimen, or required off-period has been established.
Higher research-use amounts should not automatically be assumed to produce greater longevity or telomerase effects.
Important Disclaimer
Epitalon is an investigational peptide and not approved by the FDA. This content is for educational purposes only and does not constitute medical advice.
Comments
Post a Comment